Data and Safety Monitoring Board Approves LyGenesis's Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration

The next four patients will receive a higher dose of LyGenesis's cell therapy to grow functioning liver tissue in patients with end stage liver disease PITTSBURGH, March 4, 2025 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing cell therapies for organ...